Clinical trial · Observational
Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study
NCT05719324CI-TRIAL-00063830unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective clinical study aimed at observing and evaluating the effectiveness and safety of checkpoint inhibitors in the treatment of patients with solid tumors in actual clinical applications. To explore predictors of efficacy patients with unresectable solid tumors receiving checkpoint inhibitors and develop and further validate predictive models.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival (PFS）
- timeFrame
- Up to 24 months.
- description
- PFS is defined as the time from initiation of checkpoint inhibitors until disease progression or death, whichever comes first.
Secondary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- Up to 24 months.
- description
- OS is defined as the time from initiation of checkpoint inhibitors to death or last follow-up.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old and gender is not limited. * Patients with unresectable solid tumors confirmed by pathology or histology. * Patients received checkpoint inhibitor therapy for 2 cycles or more. Exclusion Criteria: * Have a history of immunodeficiency, or suffer from other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation. * Pre-existing thyroid dysfunction that cannot be maintained within the normal range even with medical treatment. * Pregnant or breastfeeding women. * Those who have a history of psychotropic drug abuse and cannot quit or have mental disorders. * The investigator judges that other conditions are not suitable for inclusion in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.